{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T22:25:52Z","timestamp":1773440752677,"version":"3.50.1"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T00:00:00Z","timestamp":1638230400000},"content-version":"vor","delay-in-days":337,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Trial Information<\/jats:title>\n                  <jats:p>ClinicalTrials.gov \u00a0Identifier: NCT02525237 Sponsor: Xiaochun Zhang Principal Investigator: Xiaochun Zhang IRB Approved: Yes<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Lessons Learned<\/jats:title>\n                  <jats:p>Apatinib combined with S-1 was not superior to other chemotherapy regimens as first-line therapy for advanced gastric cancer. There was a tendency for patients with lymph node metastasis to have prolonged median progression-free survival and median overall survival, compared with patients with liver metastasis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The best choice of first-line chemotherapy regimen for patients with metastatic gastric cancer is still debated. We combined apatinib and S-1 as a new first-line therapy to treat advanced gastric cancer. The efficacy and safety of the combination were assessed, with the goal of determining the most appropriate subgroup of patients who could benefit from this new regimen.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This study was an open, exploratory single-arm, phase II trial. Enrolled patients received apatinib plus S-1 treatment (apatinib, 500 mg, once a day [qd], days 1\u201321; S-1, 40 mg\/m2, bid, days 1\u201314). The primary endpoints were progression-free survival (PFS) and safety of this new regimen. Next-generation sequencing was used to explore potential biomarkers.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 30 patients were enrolled. The median progression-free survival (mPFS) was 4.21 months (95% confidence interval [CI], 2.29\u20136.13 months). The median overall survival (mOS) was 7.49 months (95% CI, 4.81\u201310.17 months). Patients with lymph node metastasis had prolonged mPFS and mOS when compared with those with liver metastasis (mPFS, 4.21 vs. 1.84 months; mOS, 8.21 vs. 6.31 months, p = .08). The most common grade 3 to 4 adverse events were abdominal pain, dizziness, and diarrhea. Gene mutation profiles between the two subgroups were significantly different.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Apatinib combined with S-1 was not superior to other chemotherapy regimens as first-line therapy for advanced gastric cancer. Toxicity was consistent with known profiles when given as monotherapy. There was a tendency toward prolonged mPFS and mOS in patients with lymph node metastasis compared with patients with liver metastasis, which could support the need to design a future clinical trial with a better defined patient population.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/onco.13613","type":"journal-article","created":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T10:09:03Z","timestamp":1606471743000},"page":"e374-e381","source":"Crossref","is-referenced-by-count":11,"title":["Apatinib in Combination with S-1 as First-Line Treatment in Patients with Advanced Metastatic Gastric Cancer: Results from an Open, Exploratory, Single-Arm, Phase II Trial"],"prefix":"10.1093","volume":"26","author":[{"given":"Na","family":"Zhou","sequence":"first","affiliation":[{"name":"Precision Medicine Center of Oncology, the Affiliated Hospital of Qingdao University, Qingdao, Shandong, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuantao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Precision Medicine Center of Oncology, the Affiliated Hospital of Qingdao University, Qingdao, Shandong, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Liu","sequence":"additional","affiliation":[{"name":"Precision Medicine Center of Oncology, the Affiliated Hospital of Qingdao University, Qingdao, Shandong, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kewei","family":"Liu","sequence":"additional","affiliation":[{"name":"Precision Medicine Center of Oncology, the Affiliated Hospital of Qingdao University, Qingdao, Shandong, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanqun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology, the Affiliated Hospital of Qingdao University, Qingdao, Shandong, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Zhu","sequence":"additional","affiliation":[{"name":"Precision Medicine Center of Oncology, the Affiliated Hospital of Qingdao University, Qingdao, Shandong, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianli","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, the Affiliated Hospital of Qingdao University, Qingdao, Shandong, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Man","family":"Jiang","sequence":"additional","affiliation":[{"name":"Precision Medicine Center of Oncology, the Affiliated Hospital of Qingdao University, Qingdao, Shandong, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, the Affiliated Hospital of Qingdao University, Qingdao, Shandong, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaochun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Precision Medicine Center of Oncology, the Affiliated Hospital of Qingdao University, Qingdao, Shandong, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,12,28]]},"reference":[{"key":"2021122512035441700_onco13613-bib-0001","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/annonc\/mdn717","article-title":"Capecitabine\/cisplatin versus 5-fluorouracil\/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial","volume":"20","author":"Kang","year":"2009","journal-title":"Ann Oncol"},{"key":"2021122512035441700_onco13613-bib-0002","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2009.25.4706","article-title":"Multicenter phase III comparison of cisplatin\/S-1 with cisplatin\/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: The FLAGS Trial","volume":"28","author":"Ajani","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122512035441700_onco13613-bib-0003","doi-asserted-by":"crossref","first-page":"3968\u20133976","DOI":"10.1200\/JCO.2011.36.2236","article-title":"Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study","volume":"29","author":"Ohtsu","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122512035441700_onco13613-bib-0004","doi-asserted-by":"crossref","first-page":"2196\u20132203","DOI":"10.1093\/annonc\/mdw423","article-title":"Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: A randomized, double-blind, multicenter phase II trial","volume":"27","author":"Yoon","year":"2016","journal-title":"Ann Oncol"},{"key":"2021122512035441700_onco13613-bib-0005","first-page":"3219\u20133225","article-title":"Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: Results from a randomized, placebo-controlled, parallel-arm, phase II trial","volume":"31","author":"Li","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122512035441700_onco13613-bib-0006","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","article-title":"Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction","volume":"34","author":"Li","year":"2016","journal-title":"J Clin Oncol"},{"key":"2021122512035441700_onco13613-bib-0007","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1080\/14740338.2018.1535592","article-title":"The safety of apatinib for the treatment of gastric cancer","volume":"17","author":"Geng","year":"2018","journal-title":"Expert Opin Drug Saf"},{"key":"2021122512035441700_onco13613-bib-0008","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet"},{"key":"2021122512035441700_onco13613-bib-0009","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol"},{"key":"2021122512035441700_onco13613-bib-0010","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S1470-2045(18)30791-5","article-title":"Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): A double-blind, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Fuchs","year":"2019","journal-title":"Lancet Oncol"},{"key":"2021122512035441700_onco13613-bib-0011","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.canlet.2012.11.029","article-title":"Identifying molecular drivers of gastric cancer through next-generation sequencing","volume":"340","author":"Liang","year":"2013","journal-title":"Cancer Lett"},{"key":"2021122512035441700_onco13613-bib-0012","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/s12885-019-5498-3","article-title":"Assessment of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: The ARMANI phase III trial","volume":"19","author":"Di Bartolomeo","year":"2019","journal-title":"BMC Cancer"},{"key":"2021122512035441700_onco13613-bib-0013","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jcmgh.2017.01.003","article-title":"Gastric cancer genomics: Advances and future directions","volume":"3","author":"Katona","year":"2017","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"2021122512035441700_onco13613-bib-0014","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/annonc\/mdv508","article-title":"Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer","volume":"27","author":"Kuboki","year":"2016","journal-title":"Ann Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/onco.13613","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/onco.13613","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/3\/e374\/41923281\/oncolo_26_3_e374.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/3\/e374\/41923281\/oncolo_26_3_e374.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T12:04:11Z","timestamp":1640433851000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/26\/3\/e374\/6445508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,28]]},"references-count":14,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,12,28]]},"published-print":{"date-parts":[[2021,3,1]]}},"URL":"https:\/\/doi.org\/10.1002\/onco.13613","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3,1]]},"published":{"date-parts":[[2020,12,28]]}}}